Taysha Gene Therapies, Inc. cash flow to debt ratio of -512.27% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Taysha Gene Therapies, Inc.'s free cash flow has decreased 14.99% from $-81.60M last year to $-93.83M, signaling decreasing performance

Taysha Gene Therapies, Inc.'s debt to equity ratio is 0.08, which means that the company's assets are healthy financed, signaling financial stability.

Taysha Gene Therapies, Inc.'s debt has decreased relative to shareholder equity from 0.88 last year to 0.08 today, signaling strengthened financials

Taysha Gene Therapies, Inc. has a net cash position, so leverage is healthy.

Taysha Gene Therapies, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Taysha Gene Therapies, Inc.'s profit margin has decreased (62.22%) in the last year from -1.07K% to -1.74K%, signaling decreasing performance

Taysha Gene Therapies, Inc.'s short-term assets of $324.65M exceed its short-term liabilities of $26.55M

Taysha Gene Therapies, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Taysha Gene Therapies, Inc.'s return on equity of -56.07%, is lower than 15.00%, indicating bad performance

Taysha Gene Therapies, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Taysha Gene Therapies, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Taysha Gene Therapies, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Taysha Gene Therapies, Inc. has negative free cash flow, indicating cash burn

Taysha Gene Therapies, Inc.'s yearly earnings has decreased 22.06% since last year from $-89.30M to $-109.00M, signaling decreasing performance

Taysha Gene Therapies, Inc.'s yearly revenue has increased 17.28% since last year from $8.33M to $9.77M, signaling increasing performance

ROIC -47.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Taysha Gene Therapies, Inc.'s 3-year revenue CAGR of 57.49% is positive, indicating growing revenue over the past 3 years

Taysha Gene Therapies, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Taysha Gene Therapies, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Taysha Gene Therapies, Inc. has insufficient data to evaluate this check.

Taysha Gene Therapies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Taysha Gene Therapies, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Taysha Gene Therapies, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Taysha Gene Therapies, Inc. has insufficient data to evaluate this check.

Taysha Gene Therapies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Taysha Gene Therapies, Inc. has a price-to-book ratio of 11.02x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Taysha Gene Therapies, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue